Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

GlobeNewswire 4 days ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire November 22, 2024

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

GlobeNewswire November 11, 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

GlobeNewswire November 7, 2024

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire October 23, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

GlobeNewswire October 22, 2024

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

GlobeNewswire October 15, 2024

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

GlobeNewswire October 10, 2024

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 8, 2024

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

GlobeNewswire September 5, 2024

Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2024

Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire August 7, 2024

Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

GlobeNewswire June 11, 2024

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

GlobeNewswire June 4, 2024

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

GlobeNewswire June 3, 2024

Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Indaptus Therapeutics to Present New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 29, 2024

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company's Broad-Based, "Pulse-Prime" Immuno-Oncology Therapy for Advanced Solid Tumors

GlobeNewswire May 22, 2024